At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 95 enrolled
Drug / intervention
BG9418 (interferon beta-1a) +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label, Multicenter Study to Evaluate the Safe and Effective Use of the Single-Use Autoinjector With an Avonex® Prefilled Syringe in Multiple Sclerosis Subjects
In Brief
A Phase 3 clinical trial evaluating single-use autoinjector with a prefilled liquid Avonex syringe, Avonex prefilled syringe via manual IM injection, and 1 other intervention for Multiple Sclerosis. Completed, enrolled 95 participants across 16 sites.
Detailed Summary
The primary objective of the study was to evaluate the safe and effective use of the single-use autoinjector for the intramuscular (IM) delivery of liquid Avonex® (interferon beta-1a) in participants with multiple sclerosis (MS).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Sclerosis
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartJan 2009
First PostedJan 2009
Primary CompletionJul 2010
Study CompletionOct 2010
TodayJul 2026
First PostedJan 23, 2009
Enrollment StartJan 1, 2009
Primary CompletionJul 1, 2010
Study CompletionOct 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 17.4 years ago
Interventions
single-use autoinjector with a prefilled liquid Avonex syringedevice
Avonex prefilled syringe via manual IM injectiondevice
BG9418 (interferon beta-1a)drug